The US Food and Drug Administration closed out the week with a late-Friday approval of Esperion Therapeutics Inc.’s Nexletol, a new oral non-statin LDL-cholesterol lowering agent.
Earlier in the week, FDA’s new product approvals included a new formulation of an NSAID as an IV treatment for pain, a new transdermal contraceptive patch, and a prescription laxative
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?